Meridica was established in May 2001 as part of PA Consulting Group’s venture programme. Following a licensing and equity deal with Pfizer Inc. for Meridica’s Dry Powder Inhaler, Xcelovair™, PA subsequently sold the remainder of the shares in this successful venture for $125MM to Pfizer.
PA demerged its successful venture arm, Ipex Capital, in June 2008.
PA Consulting and Ipex Capital have a strong pedigree in successfully exploiting and incubating intellectual property, technology and know-how.
PRINT
EMAIL
TWITTER
LINKEDIN
FACEBOOK
FEEDS